- Home
- NYT vs ITCI Comparison
NYT vs ITCI Comparison
Compare NYT & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYT
- ITCI
- Stock Information
- Founded
- NYT 1851
- ITCI 2002
- Country
- NYT United States
- ITCI United States
- Employees
- NYT N/A
- ITCI N/A
- Industry
- NYT Newspapers/Magazines
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- NYT Consumer Discretionary
- ITCI Health Care
- Exchange
- NYT Nasdaq
- ITCI Nasdaq
- Market Cap
- NYT 9.1B
- ITCI 8.0B
- IPO Year
- NYT N/A
- ITCI N/A
- Fundamental
- Price
- NYT $52.77
- ITCI $75.22
- Analyst Decision
- NYT Buy
- ITCI Strong Buy
- Analyst Count
- NYT 5
- ITCI 11
- Target Price
- NYT $50.60
- ITCI $93.55
- AVG Volume (30 Days)
- NYT 672.9K
- ITCI 462.3K
- Earning Date
- NYT 08-07-2024
- ITCI 10-31-2024
- Dividend Yield
- NYT 0.99%
- ITCI N/A
- EPS Growth
- NYT 52.50
- ITCI N/A
- EPS
- NYT 1.62
- ITCI N/A
- Revenue
- NYT $2,467,072,000.00
- ITCI $564,526,000.00
- Revenue This Year
- NYT $8.54
- ITCI $46.60
- Revenue Next Year
- NYT $6.68
- ITCI $37.06
- P/E Ratio
- NYT $32.35
- ITCI N/A
- Revenue Growth
- NYT 5.50
- ITCI 54.31
- 52 Week Low
- NYT $39.73
- ITCI $45.50
- 52 Week High
- NYT $56.49
- ITCI $84.89
- Technical
- Relative Strength Index (RSI)
- NYT 42.50
- ITCI 53.93
- Support Level
- NYT $52.23
- ITCI $73.05
- Resistance Level
- NYT $54.90
- ITCI $76.34
- Average True Range (ATR)
- NYT 0.82
- ITCI 1.67
- MACD
- NYT -0.31
- ITCI 0.19
- Stochastic Oscillator
- NYT 16.02
- ITCI 75.60
About NYT New York Times Company (The)
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as NYTimes and various smartphone applications. The company has two segments New York Times Group and The Athletic. The company generates the majority of its revenue from the NYTG segment. The NYTG and The Athletic segments derive revenue from subscriptions, Advertising, and others, where the major source of revenue for both segments is subscription.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.